7642-58-2

Basic information

• Product Name: (7alpha,17beta)-17-hydroxy-7-methylandrost-4-en-3-one
• Synonyms: (7alpha,8xi,17beta)-17-hydroxy-7-methylandrost-4-en-3-one; 17-.beta.-hydroxy-7-.alpha.-methyl-androst-4-en-3-one; 17beta-Hydroxy-7alpha-methylandrost-4-en-3-one; 17-beta-hydroxy-7-alpha-methyl-androst-4-en-3-one (9CI); 7-.alpha.-methyltestosterone; 7.alpha.-Methyltestosterone; 7alpha-Methyltestosterone; 7-alpha-Methyltestosterone; 7A-METHYLTESTOSTERONE; Androst-4-en-3-one, 17.beta.-hydroxy-7.alpha.-methyl-
• CAS NO: 7642-58-2
• Molecular Formula: C₂₀H₃₀O₂
• Molecular Weight: 302.451
• Mol File: 7642-58-2.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 438.9°C at 760 mmHg
• Flash Point: 187.1°C
• Density: 1.1g/cm³
• Vapor Pressure: 1.52E-09mmHg at 25°C
• Refractive Index: 1.553
• CAS DataBase Reference: (7alpha,17beta)-17-hydroxy-7-methylandrost-4-en-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: (7alpha,17beta)-17-hydroxy-7-methylandrost-4-en-3-one(7642-58-2)
• EPA Substance Registry System: (7alpha,17beta)-17-hydroxy-7-methylandrost-4-en-3-one(7642-58-2)

Safety Data

• Hazardous Substances Data: 7642-58-2(Hazardous Substances Data)

Usage

General Description

(7alpha,17beta)-17-hydroxy-7-methylandrost-4-en-3-one is a steroid hormone and a derivative of testosterone. It is also known as methylandrostenolone or methandienone. This chemical compound is commonly used as an anabolic steroid to promote muscle growth and improve athletic performance. It is often taken orally and has a rapid onset of action, making it popular among bodybuilders and athletes seeking to enhance their physical abilities. However, the long-term use of this compound can lead to various adverse effects, including liver damage, cardiovascular issues, and mood changes. Due to these potential risks, the use of (7alpha,17beta)-17-hydroxy-7-methylandrost-4-en-3-one is regulated and restricted in many countries.

Upstream product

• 58-22-0 testosterone 
• 3591-23-9 6-dehydrotestosterone 
• 75-16-1 methylmagnesium bromide 
• 40272-15-9 5α-Androst-6-en-3β,5,17β-triol-3,17-diacetat 
• 15084-43-2 Acetic acid (3S,7S,8R,9S,10R,13S,14S,17S)-17-acetoxy-7-iodomethyl-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester 
• 13890-57-8 3β,17β-Diacetoxy-7α-methyl-androst-5-en 
• 15825-36-2 7α-Methyl-androst-5-en-3β,17β-diol 
• 50880-57-4 RMI 12936 

Relevant articles and documents

-

-

EMBODIMENTS OF MONOMER AND OLIGOMER COMPOUNDS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME

The invention relates to embodiments of monomer and oligomer compounds intended for use as contraceptive agents. The embodiments of monomer compounds of the present invention comprise substituents that facilitate the ability of the compounds to exhibit pr

ANDROGEN AS A MALE CONTRACEPTIVE AND NON-CONTRACEPTIVE ANDROGEN REPLACEMENT

The present invention relates to methods of providing male contraception using a specified androgen without the need of a separate sterilizing agent. The invention also describes methods for non-contraceptive androgen replacement and devices useful for carrying out both processes.

Method for androgen supplementation

A particular group of androgens is not metabolized to their 5α-reduced form in the prostate and other tissues. Thus, administration of these compounds--testosterone derivatives with a non-hydrogen substituent in the 6α or 7α position--allows one to provide androgen supplementation therapy without stimulating abnormal prostate growth. A preferred compound for use in the invention is 7α-methyl-19-nortestosterone.